This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Example content

Adverse event reporting can be found at the bottom of the page

Treatment Pathways and Management of Haemato-oncology Patients with Invasive Fungal Infection

Prescribing information can be found at the bottom of the page.


Join us on 15 April 2024 to hear from Dr Nabeela Mughal, Consultant in Infectious Diseases Microbiology & Virology discussing Treatment Pathways and Management of Haemato-oncology Patients with Invasive Fungal Infection followed by a live interactive Q&A. 

This promotional meeting is organised and funded by Pfizer Ltd for UK HCP's and may include reference to medicines or vaccines promoted by Pfizer.     
                     
The content for this meeting has been developed in line with Summary of Product Characteristics for Great Britain and Northern Ireland.

This meeting is available to join virtually.  There will be local HCPs attending in-person and no travel or accommodation costs will be supported to attend this meeting.

Prescribing information can be found at the bottom of the page.


Join us on 15 April 2024 to hear from Dr Nabeela Mughal, Consultant in Infectious Diseases Microbiology & Virology discussing Treatment Pathways and Management of Haemato-oncology Patients with Invasive Fungal Infection followed by a live interactive Q&A. 

This promotional meeting is organised and funded by Pfizer Ltd for UK HCP's and may include reference to medicines or vaccines promoted by Pfizer.     
                     
The content for this meeting has been developed in line with Summary of Product Characteristics for Great Britain and Northern Ireland.

This meeting is available to join virtually.  There will be local HCPs attending in-person and no travel or accommodation costs will be supported to attend this meeting.

Event Date15 April 2024 13:00 BSTDuration1 Hr AudienceConsultants, Pharmacists, Specialist Registrars {{givenName}}%20{{familyName}}%20has%20shared%20a%20resource%20with%20you%3B%20please%20click%20the%20link%20below%3A%0D%0A%0D%0A{{URL}}%0D%0A%0D%0AThank%20you%2C%0D%0A{{givenName}}%20{{familyName}}
Agenda
Meeting Agenda 12:50 - 13:00Joining & Registration
13:00 - 13:05Welcome & Introduction
13:05 - 13:50Treatment Pathways and Management of Haematooncology Patients with Invasive Fungal Infection Nabeela Mughal - Dr
13:50 - 14:05Questions & Answers Nabeela Mughal - Dr
14:05Meeting close
Speakers
Event Speakers
Nabeela Mughal, Dr
Nabeela Mughal, DrConsultant Infectious Diseases Microbiology & Virology, Chelsea and Westminster NHS Foundation Trust

Dr Nabeela Mughal is a consultant in Infectious Diseases, Clinical Microbiology and Virology, with special interests in healthcare associated infection, infection prevention and control, outbreak management and antimicrobial and antifungal stewardship. Dr Mughal leads on advancing excellence in patient care through the development and delivery of patient pathways incorporating rapid diagnostic tools, providing ward to board assurance at an executive board level. Dr Mughal is an established senior leader and her experience spans policy development, sustainability, patient pathways, leadership and governance for infection related aspects of care.    

Dr Mughal works clinically across secondary and tertiary care for patients with acute and chronic infections in London and is also a strategic member of the North West London Infection Prevention and Control Group for the Integrated Care System (ICS),  reviewing and shaping infection strategy and driving forward improvements at a regional level. 

Her qualifications include MBBS, BSc, MSc in clinical microbiology, Fellow of the Higher Education Academy (FHEA) and Masters in Education with merit (MEd) and she is a Fellow of the Royal College of Pathologists and a Member of the Royal College of Physicians.   

Cresemba®(isavuconzole) 

Prescribing Information

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

PP-CRB-GBR-2429. March 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​